Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Royalty Pharma plc
  6. Summary
    RPRX   GB00BMVP7Y09

ROYALTY PHARMA PLC

(RPRX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/11/2021 10/12/2021 10/13/2021 10/14/2021 10/15/2021 Date
36.13(c) 36.07(c) 35.83(c) 37.06(c) 38.39(c) Last
1 167 037 1 126 166 1 358 796 755 534 1 841 376 Volume
+1.80% -0.17% -0.67% +3.43% +3.59% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 2 158 M - -
Net income 2021 1 367 M - -
Net Debt 2021 4 580 M - -
P/E ratio 2021 13,6x
Yield 2021 1,82%
Sales 2022 2 233 M - -
Net income 2022 1 476 M - -
Net Debt 2022 5 452 M - -
P/E ratio 2022 13,7x
Yield 2022 1,96%
Capitalization 16 393 M 16 393 M -
EV / Sales 2021 9,72x
EV / Sales 2022 9,78x
Nbr of Employees -
Free-Float 45,3%
More Financials
Company
Royalty Pharma plc is engaged in investing in late stage biopharmaceutical products. The Company invests in academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The Company’s portfolio of pharmaceutical investment includes investments in commercial products and development-stage product candidates. Its portfolio... 
Sector
Pharmaceuticals
Calendar
11/17Earnings Release
More about the company
Ratings of Royalty Pharma plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about ROYALTY PHARMA PLC
10/15ROYALTY PHARMA : Keeps Q4 Dividend Unchanged at $0.17 a Share, Payable Dec. 15 to Sharehol..
MT
10/15ROYALTY PHARMA : Declares Fourth-Quarter 2021 Dividend
GL
10/15Royalty Pharma plc Declares Dividend for the Fourth Quarter of 2021, Payable on Decembe..
CI
10/11PRESS RELEASE : MorphoSys' Licensing Partner Roche Received Breakthrough Therapy Designati..
DJ
09/30INSIDER SELL : Royalty Pharma
MT
09/06ROYALTY PHARMA : To present at upcoming investor conferences
AQ
09/03ROYALTY PHARMA : to Present at Upcoming Investor Conferences
AQ
08/25ROYALTY PHARMA : UBS Adjusts Royalty Pharma PT to $48 From $52, Maintains Buy Rating
MT
08/16ROYALTY PHARMA : Morgan Stanley Adjusts Price Target on Royalty Pharma to $46 From $51, Ma..
MT
08/11SECTOR UPDATE : Health Care Stocks Mixed Premarket Wednesday
MT
08/11ROYALTY PHARMA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS O..
AQ
08/11ROYALTY PHARMA : Q2 Income Steady, Higher Revenue Beats Estimates; Shares Rise
MT
08/11ROYALTY PHARMA : Q2 Earnings Snapshot
AQ
08/11ROYALTY PHARMA PLC : Results of Operations and Financial Condition, Financial Statements a..
AQ
08/11ROYALTY PHARMA : Earnings Flash (RPRX) RP MANAGEMENT LLC Posts Q2 Revenue $555M, vs. Stree..
MT
More news
News in other languages on ROYALTY PHARMA PLC
10/15Royalty Pharma plc déclare un dividende pour le quatrième trimestre de 2021, payable le..
10/11FDA gibt Morphosys-Alzheimerantikörper den Status Therapiedurchbruch
10/11Alzheimer-Mittel von Morphosys und Roche vor möglicher US-Zulassung
10/11MorphoSys' Lizenzpartner Roche erhält von US-Gesundheitsbehörde FDA den Status Therapie..
09/30VENTE D'INITIÉS : Royalty Pharma
More news
Analyst Recommendations on ROYALTY PHARMA PLC
More recommendations
Chart ROYALTY PHARMA PLC
Duration : Period :
Royalty Pharma plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROYALTY PHARMA PLC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 38,39 $
Average target price 51,43 $
Spread / Average Target 34,0%
EPS Revisions
Managers and Directors
Pablo Gerardo Legorreta Chairman & Chief Executive Officer
Terrance Patrick Coyne Chief Financial Officer & Executive Vice President
James F. Reddoch Chief Scientific Officer
George Lloyd Executive VP-Investments & General Counsel
Errol B. de Souza Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ROYALTY PHARMA PLC-23.30%16 393
JOHNSON & JOHNSON2.49%424 619
ROCHE HOLDING AG16.59%339 442
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.12.71%232 621
ELI LILLY AND COMPANY40.89%215 657